

May 27, 2021

Contents

Lab Analyte & Panel Additions and Updates	2
Medications	4
Additions	4
Updates	4
Regimens.....	5
Additions	5
Updates	5
Renamed Regimens	6
Research.....	6
Regimen Additions	6
Updates	7
Billing: HCPCS Code Updates	8

Lab Analyte & Panel Additions and Updates

- 13q-/-13 - 1R1G total counts
- 13q-/-13 - 2R1G total counts
- 13q-/-13 - 2R2G total counts
- 13q-/-13 - nuclei analyzed
- 13q-/-13 - result
- 1p32.3/1q21 FISH interpretation
- 1p32.3/1q21 FISH nomenclature
- 1p32/1q21 - >=2R1G total counts
- 1p32/1q21 - >3R>=2G total counts
- 1p32/1q21 - 2R2G total counts
- 1p32/1q21 - 3R2G total counts
- 1p32/1q21 - 3R3G total counts
- 1p32/1q21 - nuclei analyzed
- 1p32/1q21 - result
- 8q24 MYC FISH nomenclature
- BCL2 (18q21) - 1R1G1F total counts
- BCL2 (18q21) - 2F total counts
- BCL2 (18q21) - nuclei analyzed
- BCL2 (18q21) result
- BCL6 (3q27) - 1R1G1F total counts
- BCL6 (3q27) - 2F total counts
- BCL6 (3q27) comments
- BCL6 (3q27) nuclei analyzed
- BCL6 (3q27) result
- Bleeding diathesis panel
- Block line
- CBC and platelet count
- CBC auto differential
- CBC components
- CBC w/ auto diff - CBC with automated differential
- CBC w/ auto diff, sodium citrate tube
- CBC w/ Retic
- CBC w/o diff
- CBC with automated differential
- CBC with manual differential
- CBC with three part differential
- CBDI IPL % of MRD
- CBDI IPL assay description
- CBDI IPL immunophenotyping diff and pop analysis
- CBDI IPL immunophenotyping interpretation
- CBDI IPL immunophenotyping summary of CPT codes
- CBDI IPL immunophenotyping summary of markers evaluated
- CBDI IPL limit of sensitivity
- CBDI IPL MRD interpretation
- CBDI IPL total mononuclear events
- CBDI IPL total WBC singlet events
- CCND1/IgH t(11;14) - 1R1G1F total counts
- CCND1/IgH t(11;14) - 1R1G2F total counts
- CCND1/IgH t(11;14) - 2R2G total counts
- CCND1/IgH t(11;14) - 2R3G total counts
- CCND1/IgH t(11;14) - result
- CCND1/IgH t(11;14) comments
- CCND1/IgH t(11;14) nuclei analyzed
- CCND1/IgH t(11;14) result
- CD4/CD8 ratio panel
- Check CBC
- CLL FISH case number
- CLL FISH chromosome analysis/karyotype (CAK)
- CLL FISH clinical information
- CLL FISH interpretation
- CLL FISH note
- CLL FISH panel
- CLL FISH pathologist
- CLL FISH specimen type
- Corrected WBC measurement
- CSF fluid analysis (after cell count)
- CSF, glucose/protein panel (after glucose)
- del(11q) ATM FISH interpretation
- del(11q) ATM FISH nomenclature
- del(13q) FISH interpretation
- del(13q) FISH nomenclature
- del(13q)/13q14/13q34 FISH interpretation
- del(13q)/13q14/13q34 FISH nomenclature
- del(17p) TP53 FISH interpretation
- del(17p) TP53 FISH nomenclature

- del(17p)TP53 FISH interpretation
- del(17p)TP53 FISH nomenclature
- del(6q) CCND3 FISH interpretation
- del(6q) CCND3 FISH nomenclature
- Factor I panel
- Factor I, mg/dL
- FGFR3/IgH t(4;14) - 1R1G1F total counts
- FGFR3/IgH t(4;14) - 1R1G2F total counts
- FGFR3/IgH t(4;14) - 2R2G total counts
- FGFR3/IgH t(4;14) - 2R3G total counts
- FGFR3/IgH t(4;14) - nuclei analyzed
- FGFR3/IgH t(4;14) - result
- FISH CPT
- FISH date
- FISH disclaimer
- FISH reviewed by
- FISH source
- Folic acid RBC panel
- For cbc check
- H and H
- Helper T-lymph CD-4 panel
- Hematocrit panel
- Hematology results
- Heme panel comments
- Hemoglobin and hematocrit determination
- Hemoglobin/Thalassemia panel
- Hemoglobinopathy profile
- Hemogram and platelet count, auto
- Highland Panel
- IgH/MAF t(14;16) - 1R1G1F total counts
- IgH/MAF t(14;16) - 1R1G2F total counts
- IgH/MAF t(14;16) - 2R2G total counts
- IgH/MAF t(14;16) - 2R3G total counts
- IgH/MAF t(14;16) - nuclei analyzed
- IgH/MAF t(14;16) - result
- IgH/MAFB t(14;20) - 1R1G1F total counts
- IgH/MAFB t(14;20) - 1R1G2F total counts
- IgH/MAFB t(14;20) - 2R2G total counts
- IgH/MAFB t(14;20) - 2R3G total counts
- IgH/MAFB t(14;20) - 3R2G total counts
- IgH/MAFB t(14;20) - nuclei analyzed
- IgH/MAFB t(14;20) - result
- LDH, CBC, COMP, PSA (after CMP)
- Leukemia/Lymphoma immunophenotyping panel
- Multiple myeloma FISH probe type
- Multiple myeloma panel by FISH
- Multiple myeloma panel by FISH summary
- MYC FISH interpretation
- Obstetric panel
- P53 (17p13.1)/ NF1 (17q11) - 1R1G total counts
- P53 (17p13.1)/ NF1 (17q11) - 1R2G total counts
- P53 (17p13.1)/ NF1 (17q11) - 2R2G total counts
- P53 (17p13.1)/ NF1 (17q11) - nuclei analyzed
- P53 (17p13.1)/ NF1 (17q11) - result
- Prenatal panel w/o HBsAg
- Protein panel, CSF
- PSA panel
- PSA reflex panel
- Site-Specific Panel
- Striated muscle Ab with reflex to titer panel
- Striated muscle antibody
- T + B-Lymphocyte differential profile
- t(11;14) CCND1/IGH FISH interpretation
- t(11;14) CCND1/IGH FISH nomenclature
- t(11;14) FISH interpretation
- t(11;14) FISH nomenclature
- t(14;16) FISH interpretation
- t(14;16) FISH nomenclature
- t(14;20) FISH interpretation
- t(14;20) FISH nomenclature
- t(4;14) FISH interpretation
- t(4;14) FISH nomenclature
- t(6;14) FISH interpretation
- t(6;14) FISH nomenclature
- Tacrolimus, highly sensitive, LC/MS/MS, ng/mL
- T-cell activation profile, CD8 subsets
- Testosterone, total, LC/MS/MS
- Thalassemia Panel
- Total Cells Counted
- Total testosterone by LC/MS/MS panel
- Trisomy 12 FISH interpretation
- Trisomy 12 FISH nomenclature
- Trisomy 5 FISH interpretation
- Trisomy 5 FISH nomenclature
- Tumor marker results
- Tumor markers panel

- Urinalysis, reagent strip without microscopy
- Urinalysis, routine and microscopic
- Urine culture & sensitivity, result 5
- Von Willebrand comprehensive panel
- von Willebrand disease plasma panel
- von Willebrand factor antigen panel
- von Willebrand factor inhibitor panel
- von Willebrand panel
- Von Willebrand type 2N panel
- Whole blood panel
- Wilshire Panel

Medications

Additions

- AdAPT-001 2.5×10e11 VP invest Intratumoral
- AdAPT-001 5×10e11 VP invest Intratumoral
- AdAPT-001 1×10e12 VP invest Intratumoral
- Balstilimab invest
- BAY 2731954 invest Oral
- Belvarafenib invest Oral
- Cobolimab invest IV
- Dostarlimab-gxly IV (Jemperli IV)
- Dr. Saunder's Mary Magic Mouthwash (Hydrocortisone-Tetracycline-Nystatin-Diphenhydramine)
- Inavolisib invest (GDC-0077 invest Oral)
- Lidocaine-Nifedipine Kit 3 %-0.5 %
- Loncastuximab Tesirine-Ipyl IV (Zynlonta IV)
- Magrolimab invest IV
- N-803 invest Subcutaneous
- Naptumomab Estafenatox invest IV
- Selitrectinib invest (BAY 2731954 invest Oral)
- TJ033721 invest IV

Updates

Medication	Update
APG-115 invest Oral	5 mg Capsule form is now available
Entrectinib Oral	50 mg Minitablet form is now available
Epoetin alfa-epbx Subcutaneous	Quick Sig Pick is now available 30,000 units subcutaneously every week
Epoetin alfa-epbx IV	Quick Sig Picks are now available 30,000 units intravenously every week 30,000 units intravenously once
Fibrinogen IV (RiaSTAP)	Quick Sig Pick is now available 1 mg intravenously Piggyback once
IPH2201 invest IV	350 mg solution form is now available

Regimens

This section does not include clinical trials.

Low Emetic Risk regimens were reviewed to confirm alignment with current NCCN guidelines. Regimens misclassified as Low were updated to reflect the correct categorization of Minimal in preparation of prechecking Granisetron, inj. beneath the PREMEDITATIONS header.

Additions

The following regimens are now available for ordering in the Regimen Library.

Regimen	Diagnoses
Carboplatin + Liposomal Doxorubicin + Bevacizumab BIOSIMILAR D1,15 Q28D	Ovarian and Primary Peritoneal Cancer Fallopian Tube Cancer
Dostarlimab-gxly Q21D (Initial)	Endometrial Cancer; Uterine Cancer
Dostarlimab-gxly Q42D (Maintenance)	Endometrial Cancer; Uterine Cancer
Fluorouracil (Bolus + CIV) D1-2 + Leucovorin + Irinotecan (FOLFIRI) + Cetuximab Q14D	Colon Cancer, Rectal Cancer
Fluorouracil (Bolus + CIV) D1-2 + Leucovorin + Oxaliplatin (FOLFOX 6, Modified) + XRT Q14D	Esophageal Cancer, Gastric Cancer
Fluorouracil CIV D1-5 + Cisplatin + Trastuzumab IV + Pembrolizumab Q21D	Esophageal Cancer, Gastric Cancer
Fluorouracil CIV D1-5 + Cisplatin + Trastuzumab IV BIOSIMILAR + Pembrolizumab Q21D	Esophageal Cancer, Gastric Cancer
FOLFOXIRI Q14D (Neoadjuvant)	Colon Cancer, Rectal Cancer
Loncastuximab tesirine-lpyl Q21D	Lymphoma, Non-Hodgkin (NHL)

Updates

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.

- Breast Cancer
- Colon Cancer
- Esophageal Cancer (Parent)
- Fallopian Tube Cancer
- Gastric Cancer
- Lymphoma, Non-Hodgkin (NHL) (Parent)
- Multiple Myeloma (MM)
- Ovarian and Primary Peritoneal Cancer
- Rectal Cancer
- Uterine Cancer (Parent)

Renamed Regimens

Previous Name	New Name
Lenalidomide D1-21 + Bortezomib D1,8,15,22 + Dexamethasone (RVD-Lite) Q35D (Part 1 of 2: Induction)	Lenalidomide D1-21 + Bortezomib D1,8,15,22 + Dexamethasone (RVD-Lite) Q35D (Part 1 of 2: Induction)
Lenalidomide D1-21 + Bortezomib D1,8,15,22 + Dexamethasone (RVD-Lite) Q35D (Part 1 of 2: Induction)	Lenalidomide D1-21 + Bortezomib D1,8,15,22 + Dexamethasone (RVD-Lite) Q35D (Part 1 of 2: Induction)
Lenalidomide D1-21 + Bortezomib D1,8,15,22 + Dexamethasone (RVD-Lite) Q35D (Part 1 of 2: Induction)	Lenalidomide D1-21 + Bortezomib D1,8,15,22 + Dexamethasone (RVD-Lite) Q35D (Part 1 of 2: Induction)
Lenalidomide D1-21 + Bortezomib D1,8,15,22 + Dexamethasone (RVD-Lite) Q35D (Part 1 of 2: Induction)	Lenalidomide D1-21 + Bortezomib D1,8,15,22 + Dexamethasone (RVD-Lite) Q35D (Part 1 of 2: Induction)
Lenalidomide D1-21 + Bortezomib D1,8,15,22 + Dexamethasone (RVD-Lite) Q35D (Part 1 of 2: Induction)	Lenalidomide D1-21 + Bortezomib D1,8,15,22 + Dexamethasone (RVD-Lite) Q35D (Part 1 of 2: Induction)
Lenalidomide D1-21 + Bortezomib D1,8,15,22 + Dexamethasone (RVD-Lite) Q35D (Part 1 of 2: Induction)	Lenalidomide D1-21 + Bortezomib D1,8,15,22 + Dexamethasone (RVD-Lite) Q35D (Part 1 of 2: Induction)
Ofatumumab D1 + Chlorambucil D1-7 Q28D	Ofatumumab + Chlorambucil D1-7 Q28D

Research

Regimen Additions

To support Data Migration, applicable clinical trial regimens for US Oncology Research have been migrated and modified for customers migrating from iKnowMed Generation 1 to iKnowMed Generation 2.

Updates

The USOR Clinical Trials listed in the table below are updated.

	Updated Reference Information			
	Updated Drug Service Order Information			
	Updated Regimen Instructions			
	Other Changes			
USOR 16104				Available for ordering: <ul style="list-style-type: none"> USOR 16104 Part F Regimen 1: Ladiratumumab Vedotin D1,8,15 Q21D USOR 16104 Part F Regimen 2: Ladiratumumab Vedotin D1,8 Q21D USOR 16104 Part F Regimen 3: Ladiratumumab Vedotin D1,8,15 Q21D
USOR 18004	X		X	
USOR 18103	X		X	Available for ordering: USOR 18103 Open-Label Extension Niraparib + Abiraterone + Prednisone
USOR 18177	X		X	
USOR 18187	X	X	X	
USOR 18263	X			
USOR 19034	X	X	X	Available for ordering: USOR 19034 Part 2 Dostarlimab or Placebo D1 + Niraparib or Placebo (PO; Daily) Q42D (Cycle 7+) No longer available for ordering: <ul style="list-style-type: none"> USOR 19034 Dostarlimab or Placebo + Paclitaxel + Carboplatin Q21D USOR 19034 Dostarlimab or Placebo Q42D
USOR 19043	X	X		
USOR 19079	X			
USOR 19120	X	X		
USOR 19226	X	X	X	
USOR 19236	X		X	
USOR 20137	X	X	X	Available for ordering: USOR 20137 Durvalumab Q28D
USOR 20144	X	X	X	No longer available for ordering: <ul style="list-style-type: none"> USOR 20144 Safety Run-In Brentuximab Vedotin + Lenalidomide D1-21 + Rituximab IV fb SQ Q21D USOR 20144 Safety Run-In Brentuximab Vedotin + Lenalidomide D1-21 + Rituximab BIOSIMILAR IV fb SQ Q21D

	Updated Reference Information			
	Updated Drug Service Order Information			
	Updated Regimen Instructions			
	Other Changes			
USOR 20186	X	X	X	Available for ordering: <ul style="list-style-type: none"> • USOR 20186 Cohort I Belvarafenib (PO; BID) Q28D • USOR 20186 Cohort J Belvarafenib (PO; BID) Q28D • USOR 20186 Cohort K Pralsetinib (PO; Daily) Q28D
USOR 20217	X			
USOR 20235	X	X		
USOR 20245				Available for ordering: <ul style="list-style-type: none"> • USOR 20245 Induction Seribantumab D1,8,15,22 Q28D (12 Weeks) • USOR 20245 Maintenance Seribantumab D1,15 Q28D • USOR 20245 Re-Induction Seribantumab D1,8,15,22 Q28D
USOR 20249		X		
USOR 20384	X		X	Available for ordering: USOR 20384 AMG 510 (PO; Daily) + Paclitaxel + Carboplatin Q21D

Billing: HCPCS Code Updates

Medication	HCPCS Code
Dostarlimab-gxly IV	J3590 per 500 mg
Human Papillomav Vac, 9-val (PF) IM	90650 per 0.5 mL
Loncastuximab Tesirine-lpyl	J3590 per 10 mg
Margetuximab invest IV	J9999 per 250 mg